- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:09 | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the AHA Scientific Sessions 2024 | 2 | Cision News | ||
| 08:00 | Cereno Scientific AB: Cereno Scientific publishes the interim report for Q3 2024 (July 1-September 30) | 7 | GlobeNewswire (Europe) | The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2024 (July 1-September 30).
Summary of the interim report for Q3 2024 (July 1-September 30)
Cereno... ► Artikel lesen | |
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 14.11. | CERENO SCIENTIFIC: BioStock has published an interview with CEO Sten R. Sörensen on the minimum 250 MSEK loan financing | 3 | Cision News | ||
| 13.11. | Preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal | 1 | Cision News | ||
| 12.11. | Cereno Scientific - New SEK250m financing secures runway into 2026 | 180 | Edison Investment Research | Cereno Scientific has announced a new financing arrangement of at least SEK250m, with net proceeds expected to extend the runway into 2026, past several key clinical milestones. Secured from Fenja Capital... ► Artikel lesen | |
| 12.11. | CERENO SCIENTIFIC: Elicera's CEO: "One of the biggest milestones in our history" | 2 | Cision News | ||
| 11.11. | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 | 1 | Cision News | ||
| 06.11. | Cereno Scientific's CEO on novel therapies for rare diseases | 1 | Cision News | ||
| 31.10. | Cereno Scientific participates at DNB Nordic Healthcare Conference 2024 | 2 | Cision News | ||
| 30.10. | Cereno Scientific presents at BioStock Life Science Summit 2024 | 1 | Cision News | ||
| 25.10. | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014 | 2 | Cision News | ||
| 25.10. | Cereno Scientific - CMD highlights a 'rare' portfolio refocus | 229 | Edison Investment Research | Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its development pipeline and strategic objectives. The key takeaway was its decision to focus on the rare disease... ► Artikel lesen | |
| 22.10. | CERENO SCIENTIFIC: BioStock has published an interview with CEO Sten R. Sörensen on IPF as the initial indication for CS014 and the Company's strengthened focus on rare diseases | 3 | Cision News | ||
| 22.10. | The temperature of Cereno Scientific after major news | 1 | Cision News | ||
| 17.10. | Cereno Scientific presents an updated agenda for the Capital Markets Day October 17th, 2024 | 1 | Cision News | ||
| 16.10. | Cereno Scientific to attend BIO-Europe in Stockholm, November 4-6, 2024 | 1 | Cision News | ||
| 15.10. | Cereno Scientific presents the agenda for the upcoming Capital Markets Day to be held October 17th, 2024 | 2 | Cision News | ||
| 09.10. | Cereno Scientific to present preclinical data for drug candidate CS585 at the AHA Scientific Sessions 2024 | 2 | Cision News | ||
| 08.10. | Invitation to Cereno Scientific's Capital Markets Day on October 17, 2024 | 3 | Cision News | ||
| 07.10. | Edison Investment Research publishes Executive interview with Sten R. Sörensen, CEO, Cereno Scientific, on positive topline Phase IIa results | 1 | Cision News |
Seite:
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 21,370 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| RECURSION PHARMACEUTICALS | 6,040 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| EVOTEC | 9,905 | 0,00 % | BASF, Evotec, GFT, Knaus Tabbert, LVMH, Wienerberger - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| QUANTUM-SI | 1,400 | 0,00 % | Nvidia Partners With Quantum-Si To Advance Single-Molecule Analysis | ||
| QIAGEN | 39,695 | +2,20 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| 89BIO | 7,980 | 0,00 % | 89bio, Inc.: 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 | SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for... ► Artikel lesen | |
| LONGBOARD PHARMACEUTICALS | 59,76 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| STRUCTURE THERAPEUTICS | 32,710 | 0,00 % | Structure Therapeutics reports Q3 results | ||
| SPRINGWORKS THERAPEUTICS | 37,440 | 0,00 % | SpringWorks started at outperform by Evercore ahead of FDA decision | ||
| 4D MOLECULAR THERAPEUTICS | 8,410 | 0,00 % | Analyst Expectations For 4D Molecular Therapeutics' Future | ||
| DYNE THERAPEUTICS | 30,000 | 0,00 % | Wissenschaftliche Leiterin von Dyne Therapeutics verkauft Aktien im Wert von 80.539 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,740 | 0,00 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
CERENO SCIENTIFIC AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,416 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.
